I rate Elevance Health, Inc. (NYSE: ELV ) as a Buy. The healthcare plan providers industry has been severely hit, and Elevance especially so. Whether in market prices, public opinion, or financial results, things have deteriorated. But I have taken a contrarian stanceMy investing approaches are GARP, Value, and Growth. I closely follow insider buying and buybacks. Also, I pay attention to some technical analysis tools, such as Elliott Wave, EMA crossovers, and chart patterns.Analyst’s Disclosure:I/we have a ...

智通财经7月18日电，美银环球研究将Elevance Health目标价从350美元下调至330美元。 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-16751 220 Virginia Avenue Indianapolis, Indiana 46204 (Address of principal executive offices) (Zip Code) Registrant's telephone ...

Key Takeaways Elevance Health's Q2 EPS of $8.84 missed estimates and declined 12.6% year over year. Higher premiums and product revenues drove a 14.3% rise in operating revenues to $49.4 billion. Rising costs in ACA and Medicaid pressured margins, with the adjusted EPS guidance cut to $30 for 2025.Elevance Health, Inc. (ELV) has reported second-quarter 2025 adjusted earnings per share (EPS) of $8.84, which missed the Zacks Consensus Estimate by 3.5%. The bottom line decreased 12.6% year over year.Operatin ...

For the quarter ended June 2025, Elevance Health (ELV) reported revenue of $49.42 billion, up 14.3% over the same period last year. EPS came in at $8.84, compared to $10.12 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $48.15 billion, representing a surprise of +2.64%. The company delivered an EPS surprise of -3.49%, with the consensus EPS estimate being $9.16.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Stre ...

Elevance Health (ELV) Q2 2025 Earnings Call July 17, 2025 08:30 AM ET Company ParticipantsNathan Rich - VP - IRGail Boudreaux - President, CEO & DirectorMark Kaye - EVP & CFOAndrew Mok - DirectorA.J. Rice - Managing DirectorLisa Gill - Managing DirectorFelicia Norwood - EVP & President - Government Health BenefitsLance Wilkes - Managing DirectorBen Hendrix - Vice PresidentJoshua Raskin - Partner - Managed Care & ProvidersDave Windley - Managing DirectorPeter Haytaian - EVP, President - Carelon & CarelonRxWh ...

Financial Data and Key Metrics Changes - Elevance Health reported second quarter GAAP diluted earnings per share of $7.72 and adjusted diluted earnings per share of $8.84, with a revised full year 2025 adjusted EPS guidance of approximately $30 [14][19] - Operating revenue was $49.4 billion, an increase of 14% year over year, driven by higher premium yields and recent acquisitions [14][15] - The consolidated benefit expense ratio increased to 88.9%, up 260 basis points year over year, primarily due to pressures in the ACA and Medicaid businesses [15][17] Business Line Data and Key Metrics Changes - The Medicare Advantage portfolio showed continued strength, with cost trends in line with expectations [6][17] - CarillonRx experienced over 20% growth in operating revenue, while Carillon services delivered more than 50% growth in revenue [18][19] - Membership decreased to 45.6 million, down approximately 200,000 sequentially, attributed to a reduction in Medicaid membership and lower effectuation rates in the ACA business [14][15] Market Data and Key Metrics Changes - The ACA market is experiencing elevated morbidity due to shifts from Medicaid, with approximately 70% of the total impact attributed to risk pool acuity [26][36] - Medicaid cost trends decelerated in the second quarter but at a slower pace than expected, with higher acuity and increased member utilization [16][17] - The company anticipates a broader market reset in 2026 due to the expiration of enhanced subsidies, which may lead to further risk pool changes [12][20] Company Strategy and Development Direction - The company is focused on executing a clear strategy to strengthen structural performance across the enterprise, with an emphasis on managing costs and deploying targeted investments [5][8] - Efforts are being made to stabilize trends in high-cost areas, including specialty services and post-acute care, while enhancing care delivery through streamlined prior authorization processes [9][10] - The company aims to improve visibility and consistency in operations while preparing for potential policy changes affecting Medicaid and ACA markets [20][62] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the disappointment in revising guidance for the second consecutive year but emphasized the commitment to transparency and strong execution [13][19] - The company is taking proactive steps to address elevated medical cost trends and is not relying on near-term recovery assumptions [7][12] - Management remains confident in the strength of the enterprise and the ability to create long-term value through operational discipline and innovation [13][19] Other Important Information - The company is utilizing AI-enabled tools to streamline clinical workflows and identify fraud, waste, and abuse [10][69] - Approximately one-third of benefit expenses are now in downside risk arrangements, supporting improved care coordination [10][12] - The company has returned approximately $2 billion to investors year-to-date, with a focus on maintaining flexibility for strategic investments [19][72] Q&A Session Summary Question: Can you help delineate the pressure you're seeing in the ACA business? - Management identified three principal factors: increased risk pool acuity, higher utilization in several cost categories, and inappropriate coding tactics contributing to inflated costs [22][25] Question: Can you size the relative impact of ACA and Medicaid in the guidance revision? - The reduction in guidance is slightly more weighted towards ACA, with ongoing enrollment losses in Medicaid contributing to elevated morbidity [29][35] Question: How do you think about the dynamic of Medicaid margins? - Management expects Medicaid margins to show year-over-year improvement in the back half of the year, despite ongoing challenges [42][100] Question: Can you talk about Medicare Advantage trends and bid strategy? - Medicare Advantage trends remain elevated and consistent with expectations, with a disciplined approach to bids for 2026 focused on margin recovery [46][48] Question: What are you doing differently in terms of cost structure initiatives? - The company is transforming processes using technology and AI to manage costs and identify trends earlier, with a focus on responsible innovation [66][69] Question: How is the current environment affecting capital allocation strategy? - The company is maintaining a flexible capital allocation strategy, focusing on opportunistic share repurchases while integrating recent acquisitions [72][73]

Financial Performance - Elevance Health's operating revenue for 2Q 2025 grew by 143% to $494 billion [7, 9] - The medical loss ratio was 889% [9] - Adjusted operating expense ratio improved by 140 bps to 100% [9] - Operating cash flow was $21 billion [9] - Adjusted diluted earnings per share (EPS) decreased by 142% to $884 [7] Segment Results - Health Benefits operating revenue increased by 119% to $416 billion [11] - Health Benefits adjusted operating margin decreased by 200 bps to 38% [12] - Carelon revenue increased by 358% to $181 billion [14] - CarelonRx revenue increased by 213% to $1064 billion [33] - Carelon Services revenue increased by 637% to $7441 billion [33] Strategic Focus - Elevance Health is focused on simplifying healthcare, affordability, and accessibility for consumers [3, 5] - The company aims to deepen clinical and business partnerships with care providers [4, 5] - Elevance Health is targeting at least 12% average annual growth in Adjusted Diluted Earnings Per Share [19, 20]

Elevance Health cut its profit outlook for the year on higher medical costs in Affordable Care Act plans and lower reimbursement from Medicaid https://t.co/1bKWjlk348 ...

E A R N I N G S R E L E A S E ELEVANCE HEALTH REPORTS SECOND QUARTER 2025 RESULTS Indianapolis, IN - July 17, 2025 - Elevance Health, Inc. (NYSE: ELV) reported second quarter 2025 results. "In the second quarter, Elevance Health made meaningful progress in delivering an experience that is simple and personal to those we serve, while advancing our efforts to enhance efficiency across the healthcare system. We are updating our outlook to reflect elevated medical cost trends in ACA and slower rate alignment in ...